IOANNIS GRIVEAS

Dr. IOANNIS GRIVEAS

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005
Verified
Journal Article
Closed access
IGIOANNIS GRIVEAS
IOANNIS GRIVEAS
GVGeorge Visvardis
George Visvardis
AFAleka Fleva
Aleka Fleva
DPDorothea Papadopoulou
Dorothea Papadopoulou
EMEftathios Mitsopoulos
Eftathios Mitsopoulos
GSGeorge Sakellariou
George Sakellariou

26 July 2004 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
IGIOANNIS GRIVEAS
IOANNIS GRIVEAS
ASAggelos Sourgounis
Aggelos Sourgounis
GVGeorgios Visvardis
Georgios Visvardis
IZIoannis Zarifis
Ioannis Zarifis
PKParthena Kyriklidou
Parthena Kyriklidou
GSGeorgios Sakellariou
Georgios Sakellariou

1 January 2007 in Renal Failure
Verified
Journal Article
Closed access
IGIOANNIS GRIVEAS
IOANNIS GRIVEAS
GGG. Germanidis
G. Germanidis
GVG. Visvardis
G. Visvardis
YMY. Morice
Y. Morice
APA.S. Perelson
A.S. Perelson
DPD. Papadopoulou
D. Papadopoulou
Hepatitis C virus (HCV) infection is frequent in patients with end-stage renal disease treated by chronic dialysis, with a prevalence varying from 10-65% according to the geographical data. The prevalence is significantly associated with the duration of dialysis and the number of transfused blood products[1,2] and has dramatically declined with efficient blood screening.[3] We studied patients with acute HCV infection in a dialysis unit. The diagnosis was based on both anti-HCV detection and HCV-RNA detection. Other virological tools including HCV genotype determination was also used to tailor treatment to the individual patient and determine its efficacy for a one-year follow-up period. Seventeen patients (7 male and 10 female, mean age: 63.7 +/- 11.6 SD) with acute hepatitis C were enrolled to our study. All of them were followed up for a period of one year after the diagnosis was established. Phylogenetic analysis distinguished two separate HCV subtypes 1b, which were both responsible for this acute infection (see Figure 1). These types did not differ in their behavior on the clinical situation of our patients, as confirmed by the fact that in both groups of patients, there was only one patient who presented with acute illness. Six patients of our study group, three months after the acute infection, received pegylated interferon (Peg-IFNa2a) 135 mug for a six-month period. Four of them responded very well to therapy and at the first determination HCV RNA was below the cutoff point. One of our patients with very high HCV levels (HCV RNA > 50,000,000 IU/mL), despite receiving the same therapy, did not respond well and developed cirrhosis. In conclusion, it is clear from our experience that better information is needed about the current incidence, prevalence, and risk factors for HCV infection in dialysis patients. Algorithms for the diagnosis and management of hepatitis C should be developed by academic societies. Routine screening for hepatitis C also would allow for better definition of the natural history of hepatitis C in patients with end stage renal disease. [image omitted]Figure 1. NS 5B gene phylogenetic tree analysis of the acute hepatitis C epidemic.

16 August 2011 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
IGIOANNIS GRIVEAS
IOANNIS GRIVEAS
AGAthina Gompou
Athina Gompou
IKIlias Kyritsis
Ilias Kyritsis
GPGeorgios Papatheodorou
Georgios Papatheodorou
IAIoannis Agroyannis
Ioannis Agroyannis
SVSotiris Vrachnes
Sotiris Vrachnes

1 January 2006 in Renal Failure
Verified
Journal Article
Closed access
IGIOANNIS GRIVEAS
IOANNIS GRIVEAS
GVGeorge Visvardis
George Visvardis
GSGeorge Sakellariou
George Sakellariou
PPPloumis Passadakis
Ploumis Passadakis
ITIlias Thodis
Ilias Thodis
AFAleka Fleva
Aleka Fleva
The immune defect in hemodialysis (HD) patients is associated with a monocyte dysfunction, including an increase in the production of proinflammatory cytokines. Blood membrane contact leads to an increase in cellular activation and sequestration into the capillary bed of the lung. The influence of the sequestration on the number of mature monocytes was studied by analyzing the fate of monocytes, particularly, the CD14+CD16+ subpopulation, during HD treatment. In thirty stable HD patients, the distinct cell populations were determined by differential blood counts and flow cytometry. Patients with diabetes or systemic vasculitis, those showing evidence of infectious complications or malignancy, or those taking immunosuppressive medications were excluded from the study. Cells from this study population were analyzed before the start, 30 min thereafter, and at the end of HD treatment, each time using a different dialyzer: hemophan, methylmethacrylate (PMMA), triacetate membrane, cuprophane/vitamin E, acrylonitrile, and sodium methallylsulfonate polymer (AN69). The CD14+CD16+ subset decreased at 30 min and remained suppressed for the course of dialysis. To examine whether currently used biocompatible membranes differ in their effect on the sequestration of monocyte subpopulations, temporal monocytic changes were comparatively analyzed during HD with a different dialyzer. The drop in the first 30 min until the end of HD treatment was significant (p<0.05), very uniform, and sharp in all patients, and was independent upon membrane type. The CD14+CD16+ monocyte subpopulation showed increased and longer margination from the blood circulation during HD. Given the fact that CD14+CD16+ monocytes represent a sensitive marker for inflammation or cellular activation, the depletion of these cells may offer an easily accessible parameter that is more sensitive than complement activation for biocompatibility studies on forthcoming, improved dialyzer membranes.

1 July 2004 in Transplantation Proceedings
Verified
Journal Article
Closed access
GVG. Visvardis
G. Visvardis
IGIOANNIS GRIVEAS
IOANNIS GRIVEAS
RZR. Zilidou
R. Zilidou
DPD. Papadopoulou
D. Papadopoulou
EME. Mitsopoulos
E. Mitsopoulos
GSG. Sakellariou
G. Sakellariou